Luo Kai, Wang Xiangkun, Zhang Xudong, Liu Zhongyuan, Huang Shuai, Li Renfeng
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol. 2022 Jul 4;12:933645. doi: 10.3389/fonc.2022.933645. eCollection 2022.
In the past few decades, tumor diagnosis and treatment theory have developed in a variety of directions. The number of people dying from pancreatic cancer increases while the mortality rate of other common tumors decreases. Traditional imaging methods show the boundaries of pancreatic tumor, but they are not sufficient to judge early micrometastasis. Although carcinoembryonic antigen (CEA) and carbohydrate antigen19-9 (CA19-9) have the obvious advantages of simplicity and minimal invasiveness, these biomarkers obviously lack sensitivity and specificity. Circulating tumor cells (CTCs) have attracted attention as a non-invasive, dynamic, and real-time liquid biopsy technique for analyzing tumor characteristics. With the continuous development of new CTCs enrichment technologies, substantial progress has been made in the basic research of CTCs clinical application prospects. In many metastatic cancers, CTCs have been studied as an independent prognostic factor. This article reviews the research progress of CTCs in the treatment and prognosis of pancreatic cancer.
在过去几十年中，肿瘤诊断和治疗理论朝着多种方向发展。死于胰腺癌的人数增加，而其他常见肿瘤的死亡率下降。传统成像方法可显示胰腺肿瘤的边界，但不足以判断早期微转移。尽管癌胚抗原（CEA）和糖类抗原19-9（CA19-9）具有操作简单、侵入性极小的明显优势，但这些生物标志物明显缺乏敏感性和特异性。循环肿瘤细胞（CTC）作为一种用于分析肿瘤特征的非侵入性、动态和实时液体活检技术受到关注。随着新型CTC富集技术的不断发展，CTC临床应用前景的基础研究取得了实质性进展。在许多转移性癌症中，CTC已被作为独立的预后因素进行研究。本文综述了CTC在胰腺癌治疗和预后方面的研究进展。
